# A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT06178601** · PHASE2 · UNKNOWN · sponsor: **Shanxi Province Cancer Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT06178601
- **Lead sponsor:** Shanxi Province Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-03
- **Primary completion:** 2024-09-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178601, "A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06178601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*